Allergy Therapeutics plc (AIM:AGY)

Market Cap	474.94M +46.5%
Revenue (ttm)	57.29M +2.9%
Net Income	-48.18M
EPS	-0.01
Shares Out	6.33B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,850
Open	7.50
Previous Close	7.50
Day's Range	7.00 - 7.50
52-Week Range	6.50 - 12.10
Beta	0.85
Analysts	Strong Buy
Price Target	13.00 (+85.71%)
Earnings Date	Jun 29, 2026

About Allergy Therapeutics

Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus. It also...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 584
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: AGY

Financial Performance

In fiscal year 2025, Allergy Therapeutics's revenue was 55.04 million, a decrease of -0.28% compared to the previous year's 55.20 million. Losses were -40.13 million, 3.91% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 17, 2026

Data Sources Report a data error